Lovastatin Treatment of a Patient with a De Novo SYNGAP1 Protein Truncating Variant

J Child Adolesc Psychopharmacol. 2019 May;29(4):321-322. doi: 10.1089/cap.2018.0159. Epub 2019 Apr 4.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Autism Spectrum Disorder / drug therapy*
  • Autism Spectrum Disorder / genetics
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Intellectual Disability / genetics
  • Lovastatin / therapeutic use*
  • Male
  • ras GTPase-Activating Proteins / genetics*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • SYNGAP1 protein, human
  • ras GTPase-Activating Proteins
  • Lovastatin